| Autor: |
Martínez F; Centro para la Prevención y Control del Cáncer (CECAN), Santiago 8331150, Chile.; Facultad de Medicina, Escuela de Medicina, Universidad Andrés Bello, Viña del Mar 2531015, Chile.; Concentra Educación e Investigación Biomédica, Viña del Mar 2552906, Chile., Taramasco C; Centro para la Prevención y Control del Cáncer (CECAN), Santiago 8331150, Chile.; Facultad de Ingeniería, Universidad Andrés Bello, Viña del Mar 2531015, Chile., Espinoza M; Centro para la Prevención y Control del Cáncer (CECAN), Santiago 8331150, Chile.; Departamento de Salud Pública, Pontificia Universidad Católica de Chile, Santiago 8330023, Chile.; Unidad de Evaluación de Tecnologías en Salud, Centro de Investigación Clínica, Pontificia Universidad Católica de Chile, Santiago 8330023, Chile., Acevedo J; Centro para la Prevención y Control del Cáncer (CECAN), Santiago 8331150, Chile.; Instituto de Ciencias e Innovación en Medicina, Universidad del Desarrollo, Santiago 7550000, Chile., Goic C; Centro para la Prevención y Control del Cáncer (CECAN), Santiago 8331150, Chile.; Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8330023, Chile.; Foro Nacional del Cáncer, Santiago 8340696, Chile., Nervi B; Centro para la Prevención y Control del Cáncer (CECAN), Santiago 8331150, Chile.; Departamento de Hematología y Oncología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago 8330023, Chile. |
| Abstrakt: |
Cancer, a pervasive global health challenge, necessitates chemotherapy or radiotherapy treatments for many prevalent forms. However, traditional follow-up approaches encounter limitations, exacerbated by the recent COVID-19 pandemic. Consequently, telemonitoring has emerged as a promising solution, although its clinical implementation lacks comprehensive evidence. This report depicts the methodology of a randomized trial which aims to investigate whether leveraging a smartphone app called Contigo for disease monitoring enhances self-reported quality of life among patients with various solid cancers compared to standard care. Secondary objectives encompass evaluating the app's impact on depressive symptoms and assessing adherence to in-person appointments. Randomization will be performed independently using an allocation sequence that will be kept concealed from clinical investigators. Contigo offers two primary functions: monitoring cancer patients' progress and providing educational content to assist patients in managing common clinical situations related to their disease. The study will assess outcomes such as quality of life changes and depressive symptom development using validated scales, and adherence to in-person appointments. Specific scales include the EuroQol Group's EQ-5D questionnaire and the Patient Health Questionnaire (PHQ-9). We hypothesize that the use of Contigo will assist and empower patients receiving cancer treatment, which will translate to better quality of life scores and a reduced incidence of depressive symptoms. All analyses will be undertaken with the intention-to-treat principle by a statistician unaware of treatment allocation. This trial is registered in ClinicalTrials under the registration number NCT06086990. |
